Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EOLS 
Evolus Inc (EOLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: EOLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18.83
1 Year Target Price $18.83
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.98% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 407.52M USD | Price to earnings Ratio - | 1Y Target Price 18.83 |
Price to earnings Ratio - | 1Y Target Price 18.83 | ||
Volume (30-day avg) 7 | Beta 1.04 | 52 Weeks Range 5.71 - 17.44 | Updated Date 10/16/2025 |
52 Weeks Range 5.71 - 17.44 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.31% | Operating Margin (TTM) -20.36% |
Management Effectiveness
Return on Assets (TTM) -11.06% | Return on Equity (TTM) -18729.61% |
Valuation
Trailing PE - | Forward PE 10.06 | Enterprise Value 496805014 | Price to Sales(TTM) 1.47 |
Enterprise Value 496805014 | Price to Sales(TTM) 1.47 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA -21.5 | Shares Outstanding 64685419 | Shares Floating 50591113 |
Shares Outstanding 64685419 | Shares Floating 50591113 | ||
Percent Insiders 11.97 | Percent Institutions 90.2 |
Upturn AI SWOT
Evolus Inc
Company Overview
History and Background
Evolus, Inc. was founded in 2012 and is based in Irvine, California. It is a performance beauty company focused on providing physicians and their patients with innovative aesthetic products. Evolus launched Jeuveauu00ae, a botulinum toxin type A product, in the U.S. in 2019.
Core Business Areas
- Aesthetics: Development and commercialization of aesthetic products, primarily Jeuveau, a botulinum toxin used for the temporary improvement of moderate to severe glabellar lines (frown lines) in adults.
Leadership and Structure
The company is led by a management team with experience in the pharmaceutical and aesthetics industries. Its organizational structure consists of departments focused on sales, marketing, research & development, and operations.
Top Products and Market Share
Key Offerings
- Jeuveau: Jeuveau is Evolus' primary product, a botulinum toxin type A injection used for treating glabellar lines. Market share data is constantly changing, but Evolus is a key competitor to Allergan's Botox. Competitors: Allergan (Botox), Galderma (Dysport), Merz Aesthetics (Xeomin).
Market Dynamics
Industry Overview
The aesthetics market is growing, driven by increasing demand for non-invasive cosmetic procedures. The botulinum toxin market is a significant segment within aesthetics, dominated by established players but open to new entrants with differentiated products or pricing.
Positioning
Evolus positions itself as a performance beauty company offering a modern alternative to established brands, often focusing on appealing to a younger demographic and offering competitive pricing.
Total Addressable Market (TAM)
The global botulinum toxin market is estimated to be worth billions of dollars annually. Evolus is positioned to capture a portion of this market through Jeuveau and potentially future product offerings.
Upturn SWOT Analysis
Strengths
- Competitive pricing strategy
- Strong brand recognition with younger demographic
- Focus on aesthetic medicine
- Solely focused on aesthetics
Weaknesses
- Single product reliance (Jeuveau)
- Limited geographic reach (primarily US)
- Heavily relies on debt
- Highly competitive market
Opportunities
- Expansion into new geographic markets
- Development of new aesthetic products
- Strategic partnerships and acquisitions
- Increase market share
Threats
- Competition from established players
- Product liability lawsuits
- Changes in regulations
- Economic downturns affecting discretionary spending
Competitors and Market Share
Key Competitors
- AGN
- GHDX
- MRZ
Competitive Landscape
Evolus faces intense competition from established players with greater resources and broader product portfolios. Evolus' advantages include its competitive pricing and targeted marketing. Its disadvantages include its smaller size and limited product offerings.
Growth Trajectory and Initiatives
Historical Growth: Evolus has demonstrated revenue growth since the launch of Jeuveau, but profitability has been a challenge.
Future Projections: Analyst projections vary, but generally anticipate continued revenue growth driven by increased Jeuveau sales and market penetration.
Recent Initiatives: Recent initiatives include expanding marketing efforts, launching new product sizes, and exploring potential partnerships.
Summary
Evolus is a relatively new player in the aesthetics market with a single product, Jeuveau, competing against established giants. The company has shown revenue growth, driven by competitive pricing and targeted marketing. However, it faces challenges including reliance on a single product, intense competition, and limited geographic reach. Careful monitoring of their financial health and market expansion strategies is crucial for their continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market conditions and company performance can change rapidly. Consult a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evolus Inc
Exchange NASDAQ | Headquaters Newport Beach, CA, United States | ||
IPO Launch date 2018-02-08 | President, CEO & Director Mr. David Moatazedi | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 394 | Website https://www.evolus.com |
Full time employees 394 | Website https://www.evolus.com | ||
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.